Daniel R. Chevallard - 30 Oct 2026 Form 4 Insider Report for LENZ Therapeutics, Inc. (LENZ)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
03 Nov 2026, 19:26:43 UTC
Prior SEC filing
30 Mar 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Evert Schimmelpennink, as Attorney-in-Fact
Filing notes and source

Key filing fact

Daniel R. Chevallard filed Form 4 for LENZ Therapeutics, Inc. (LENZ) on 03 Nov 2026.

Key facts

  • This page summarizes Daniel R. Chevallard's Form 4 filing for LENZ Therapeutics, Inc. (LENZ).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 03 Nov 2026, 19:26.

Change

  • Previous filing in this sequence was filed on 30 Mar 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001706176 Primary reporting owner

Chevallard Daniel R.

Relationship
Chief Financial Officer
Address
C/O LENZ THERAPEUTICS, INC., 201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Signature
/s/ Evert Schimmelpennink, as Attorney-in-Fact
Signature date
03 Nov 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LENZ transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares
+652,063
Change %
Price
$0.000000*
Shares after
652,063
Date
30 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
652,063
Exercise price
$3.05
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Subject to the Reporting Person serving as the Issuer's Interim President and CEO through each applicable date, the shares subject to the option shall vest in four equal tranches, as follows: 25% of the shares subject to the option shall commence vesting on November 1, 2026 and vest in full on November 1, 2027; 25% of the shares subject to the option shall commence vesting on February 1, 2027 and vest in full on February 1, 2028; 25% of the shares subject to the option shall commence vesting on May 1, 2027 and vest in full on May 1, 2028; 25% of the shares subject to the option shall commence vesting on August 1, 2027 and vest in full on August 1, 2028. If the Reporting Person ceases to serve as the Issuer's Interim President and CEO for any reason, any tranche for which the vesting commencement date has not yet occurred will be forfeited, and any tranche for which the vesting commencement date has occurred will remain eligible to vest.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .